Compare Divis Laboratories with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CIPLA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CIPLA DIVIS LABORATORIES/
CIPLA
 
P/E (TTM) x 31.8 24.1 132.0% View Chart
P/BV x 7.2 2.5 291.4% View Chart
Dividend Yield % 0.6 0.7 95.8%  

Financials

 DIVIS LABORATORIES   CIPLA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
CIPLA
Mar-19
DIVIS LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,142678 168.4%   
Low Rs533484 110.2%   
Sales per share (Unadj.) Rs146.6198.2 74.0%  
Earnings per share (Unadj.) Rs33.018.5 178.3%  
Cash flow per share (Unadj.) Rs38.435.0 109.8%  
Dividends per share (Unadj.) Rs10.003.00 333.3%  
Dividend yield (eoy) %1.20.5 231.2%  
Book value per share (Unadj.) Rs222.8186.3 119.6%  
Shares outstanding (eoy) m265.47805.70 32.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.72.9 194.9%   
Avg P/E ratio x25.331.4 80.8%  
P/CF ratio (eoy) x21.816.6 131.3%  
Price / Book Value ratio x3.83.1 120.5%  
Dividend payout %30.316.2 186.9%   
Avg Mkt Cap Rs m222,318468,031 47.5%   
No. of employees `00010.822.6 47.5%   
Total wages/salary Rs m4,56128,565 16.0%   
Avg. sales/employee Rs Th3,616.07,053.1 51.3%   
Avg. wages/employee Rs Th423.81,261.5 33.6%   
Avg. net profit/employee Rs Th814.9659.1 123.6%   
INCOME DATA
Net Sales Rs m38,915159,710 24.4%  
Other income Rs m1,1344,766 23.8%   
Total revenues Rs m40,049164,475 24.3%   
Gross profit Rs m12,61730,973 40.7%  
Depreciation Rs m1,42513,263 10.7%   
Interest Rs m131,684 0.8%   
Profit before tax Rs m12,31320,791 59.2%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5435,695 62.2%   
Profit after tax Rs m8,77014,924 58.8%  
Gross profit margin %32.419.4 167.2%  
Effective tax rate %28.827.4 105.0%   
Net profit margin %22.59.3 241.2%  
BALANCE SHEET DATA
Current assets Rs m45,351124,266 36.5%   
Current liabilities Rs m6,50737,715 17.3%   
Net working cap to sales %99.854.2 184.2%  
Current ratio x7.03.3 211.5%  
Inventory Days Days12791 139.8%  
Debtors Days Days9595 100.3%  
Net fixed assets Rs m21,160105,190 20.1%   
Share capital Rs m5311,611 32.9%   
"Free" reserves Rs m58,625148,511 39.5%   
Net worth Rs m59,156150,123 39.4%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m67,832239,633 28.3%  
Interest coverage x926.813.3 6,945.4%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 86.1%   
Return on assets %12.96.9 186.8%  
Return on equity %14.89.9 149.1%  
Return on capital %20.811.8 176.0%  
Exports to sales %034.7 0.0%   
Imports to sales %21.80-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35957,410 56.4%   
Fx outflow Rs m9,04219,041 47.5%   
Net fx Rs m23,31738,368 60.8%   
CASH FLOW
From Operations Rs m7,75916,911 45.9%  
From Investments Rs m-4,783-16,687 28.7%  
From Financial Activity Rs m-3,142-3,487 90.1%  
Net Cashflow Rs m-166-3,451 4.8%  

Share Holding

Indian Promoters % 52.0 16.0 325.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.8 12.2 96.7%  
FIIs % 19.0 23.7 80.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.2 26.2 65.6%  
Shareholders   31,796 161,166 19.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - CADILA HEALTHCARE COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS